OBJECTIVE: Performance measures are widely used in healthcare, ranging from quality reporting, accountability, payment and monitoring of physicians and organizations. We sought to assess the validity and evidence for the Medicare Merit-based Incentive Payment System (MIPS) measures for obstetrics and gynecology. STUDY DESIGN: Using MIPS measures, we reviewed the 46 OB/GYN measures. A group of 4 obstetrician-gynecologists and maternal fetal medicine physicians assessed the validity of the metrics for importance, appropriate care, clinical evidence, specifications and feasibility. Measures were assessed using a 9-point scale (1-3 does not meet criteria; 4-6 meets some criteria; 7-9 meets criteria). Median scores were calculated, with measures considered valid with median rating of 7-9, not valid with median rating of 1-3, and 4-6 was uncertain. Microsoft Excel was used for analysis. RESULTS: The percentage of measures rated as uncertain validity was 43% (n¼20), with 56% rated as valid and no measures rated as non-valid. Valid measures had a range scores from 7-8.5, while measures of uncertain validity had a range of scores from 4.5-6.5. A higher percentage of measures endorsed by the national quality foundation (NQF) were considered valid (62%) compared to non-NQF endorsed measures (52% Massachusetts General Hospital, Boston, MA OBJECTIVE: Hospital policies restricting access to trial of labor after cesarean (TOLAC) are prevalent. We sought to quantify the proportion of TOLAC-eligible-women receiving prenatal care at a hospital with a TOLAC ban who opted to deliver at a hospital that offers TOLAC and to identify factors associated with this switch. STUDY DESIGN: This was a survey of TOLAC-eligible women with a single prior cesarean delivery receiving prenatal care at an urban hospital with a TOLAC ban. At a face-to-face interview conducted after 20 weeks gestation, participants were asked if they knew their hospital's TOLAC policy and how likely it was that they would switch hospitals to attempt a vaginal birth after cesarean (VBAC). Participants' delivery hospital and mode were obtained by medical record review. RESULTS: 48 women were interviewed; 69% (n¼33) were aware that their hospital had a TOLAC ban. 26 women (54%) said they were likely to switch hospitals to have a TOLAC, and 17 (35%) ultimately switched hospitals for delivery. (Figure) All but one who indicated she would not switch hospitals delivered via elective repeat cesarean delivery (ERCD), while over half of women (n¼16/26) who indicated an intention to switch hospitals did so, with a VBAC success rate of 93% (15/16). 44% of the study participants reported that their current prenatal care providers either definitely or probably thought that they should have a TOLAC, and, among these women, 62% ended up attempting VBAC. (p¼0.002). All 10 women who incorrectly thought that TOLAC was allowed delivered elsewhere; those aware of the TOLAC ban were less likely to switch. (Table) . In a multivariable logistic regression model, variables that were highly associated with transferring care included race/ethnicity other than Latina (aOR 25.2, p¼0.002), being unaware of the TOLAC ban (aOR 19.8, p¼0.001), and perceiving that a close friend/relative preferred TOLAC (aOR 17.3, p¼0.014). CONCLUSION: At this urban hospital with a TOLAC ban, more than 1/ 3 of women with a prior CD switched hospitals to undergo TOLAC. Facilitating referral to a hospital that allows TOLAC would likely benefit many women with a prior CD whose current hospital has a TOLAC ban.
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Poster Session IV 
OBJECTIVE:
The WOMAN trial identified a 19% relative reduction in death from bleeding among women receiving tranexamic acid (TXA) for treatment of postpartum hemorrhage (PPH). The population in the WOMAN trial, however, was heterogeneous and mostly from developing countries. As a result, their access to resources is often lower and a priori risk of death higher than for women in the United States (US).
The objective of this study is to identify whether TXA is cost effective when applied to a contemporary US population. STUDY DESIGN: We constructed an economic analysis in TreeAge Pro comparing TXA to usual care. Outcomes studied in the model included death from bleeding, laparotomy, cost and life years gained. We determined the probability of death from bleeding among women with PPH in the US based on data published by the National Inpatient Sample 2012-2013 and the CDC's Pregnancy Mortality System data for 2016. We utilized costs from the All Patients Refined Diagnosis Related Groups. We performed one-way sensitivity analysis and Monte Carlo modeling for a theoretical cohort of 1,000 women to assess the robustness of our findings. RESULTS: In the US in 2016, there were 3,945,875 deliveries; 3% of these would be estimated to be complicated by PPH. Probability of death from bleeding was estimated to be 3.8 per 10,000 instances of PPH with a reduction in death to 3.1 per 10,000 with the use of TXA. Base case analysis showed an incremental cost of $2.3 million per life-year gained using TXA when compared to usual care, far exceeding the standard $100,000 per life-year threshold. This finding that TXA was not cost effective vs. usual care was reproduced in 100% of the 1000 Monte Carlo trials where we varied costs and probabilities based on defined distributions (Figure 1) . In one-way sensitivity analysis, when keeping the cost of TXA constant at $187, we found that TXA becomes cost effective when the probability of death from PPH exceeds 7.2 per 10,000. Figure 2 presents findings from the two-way sensitivity analysis showing the cost-effective strategy at varying TXA costs and rates of death related to PPH. CONCLUSION: Widespread use of TXA in all women with PPH in the US (approximately 120,000 cases per year) would save 9 lives; the medication/administration costs alone to implement this protocol would exceed 22 million dollars per year. TXA was not cost effective compared to usual care in US women with PPH; however, in select settings where the probability of death from PPH is higher, it may be cost effective.
